States competing over vaccine in foreign market hurts India’s image: Delhi CM Arvind Kejriwal | Delhi News

NEW DELHI: Chief minister Arvind Kejriwal on Thursday mentioned a number of states floating world tenders for Covid-19 vaccines was detrimental for India’s picture on the earth.
In a collection of tweets, Kejriwal mentioned that there needs to be centralised procurement of vaccines. “Indian states left to compete/battle with one another within the worldwide market. UP preventing Maha, Maha preventing Orissa, Orissa preventing Delhi. The place is “India”? Portrays such a foul picture of India. India, as one nation, shud procure vaccines on behalf of all Indian states (sic),” he tweeted. “Additionally, after we strategy vaccine producers and their international locations as “India” quite than particular person states, our bargaining energy is rather more, Indian govt has rather more diplomatic area to barter with their international locations,” he added.
Later within the day, the CM welcomed the assertion of Dr VK Paul, member (well being), NITI Aayog, whereby he mentioned that the Centre and Covaxin manufacturing firm (Bharat Biotech) are keen to ask different firms that wish to produce it. Kejriwal tweeted that it’s a very welcome step by the central authorities, which can assist in ramping up vaccine manufacturing.
In the meantime, in a video convention with Union well being minister Dr Harsh Vardhan, Delhi’s well being minister Satyendar Jain requested that the Centre ought to procure vaccines from international producers on behalf of the state governments, as an alternative of states being compelled to individually float world tenders. Jain additionally urged the Centre to cap the value of vaccines at a uniform Rs 150, alleging that the vaccine producers have been making a revenue of Rs 16,000 crore on 100 crore doses.
“The 2 firms making ready the 2 vaccines, Covishield and Covaxin, should share the components for preparation of those vaccines to different firms as effectively,” Jain mentioned, including that quite a few Indian firms are able to manufacturing it and mobilising it into the marketplace for the general public.
“Third level I portrayed within the assembly was that the producers of Covaxin and Covishield have thought of this disaster to be a chance to generate excessive income,” he mentioned. Jain said that when Covishield was being provided to the Centre at Rs 150, even then the corporate was making revenue.
“The corporate is manufacturing six crore vaccines each month. Even when we go by a revenue of Rs 10 per dose, and so they give half of the vaccines to the Centre, which is three crore, the estimated revenue comes out to be Rs 30 crore,” he mentioned, including the identical vaccine is being bought to state governments at Rs 300, doubling the revenue and at Rs 400 to non-public entities, although price of manufacturing stays the identical and the revenue earned goes as much as Rs 260 per dose, contemplating price of manufacturing is Rs 140.
“By this complete estimation, the corporate generates a humongous revenue of Rs 960 crore in only one month,” he mentioned.
Jain mentioned that the common revenue involves round Rs 160 per dose of vaccine. Greater than 100 crore Indians are above the age of 18 years and would require at the very least 200 crore doses. “If we take 100 crore doses from one firm and the opposite 100 crore from one other, each of them incur a revenue of Rs 16,000 crore every,” he added.
Jain additional mentioned that Covaxin was being provided at an excellent increased charge and their revenue could be increased.
Scroll to Top